Posted by Michael Wonder on 30 Mar 2025
World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men
28 March 2025 - The MHRA has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with technetium-99m to detect cancerous lesions in men with prostate cancer.
Trofolastat has been approved for use in three clinical settings: identifying how far high-risk prostate cancer has spread before treatment, detecting recurrence in patients with rising prostate-specific antigen levels, and determining whether targeted therapies might be effective for metastatic prostate cancer patients.
